NRBO
NeuroBo Pharmaceuticals, Inc. [NRBO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRBO Stock Summary
Top 10 Correlated ETFs
NRBO
Top 10 Correlated Stocks
NRBO
In the News
NRBO Financial details
Company Rating
Neutral
Market Cap
17.71M
Income
-12.55M
Revenue
4K
Book val./share
3.28
Cash/share
4.42
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-23.08
Forward P/E
-
PEG
2.65
P/S
-
P/B
6.69
P/C
0.78
P/FCF
-1.86
Quick Ratio
5.47
Current Ratio
5.54
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-2.48
EPS next Y
-
EPS next Q
-
EPS this Y
-87.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
40%
-
-
-
-
SMA20
-22.37%
SMA50
-10.2%
SMA100
4.34%
Inst Own
125.47%
Inst Trans
0.84%
ROA
-24%
ROE
-28%
ROC
-0.95%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.888-7.6
52W High
-50.57%
52W Low
+73%
RSI
33.51
Rel Volume
0.01
Avg Volume
1.37M
Volume
11.49K
Perf Week
-12.85%
Perf Month
-44.99%
Perf Quarter
0.58%
Perf Half Y
-7.98%
-
-
-
-
Beta
-0.456
-
-
Volatility
0.07%, 0.59%
Prev Close
1.76%
Price
3.46
Change
-4.42%
NRBO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.03K | -437.95 | -157.85 | -19.01 | -2.46 | |
| Operating cash flow per share | -323.38 | -159.3 | -156.94 | -36.41 | -2.13 | |
| Free cash flow per share | -333.21 | -159.36 | -156.97 | -36.41 | -2.14 | |
| Cash per share | 638.95 | 149.31 | 169.93 | 103.71 | 4.42 | |
| Book value per share | 564.71 | 106.6 | 151.37 | 67.61 | 3.29 | |
| Tangible book value per share | 564.71 | 106.6 | 151.37 | 67.61 | 3.29 | |
| Share holders equity per share | 564.71 | 106.6 | 151.37 | 67.61 | 3.29 | |
| Interest debt per share | 4.32 | 1.97 | 0.74 | 6.81 | 0.04 | |
| Market cap | 45.71M | 85.14M | 28.24M | 1.85M | 18.76M | |
| Enterprise value | 31.92M | 75.15M | 11.92M | -31.52M | -3.47M | |
| P/E ratio | -2.04 | -2.88 | -1.85 | -0.3 | -1.5 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 2.68K | |
| POCF ratio | -6.49 | -7.91 | -1.87 | -0.16 | -1.74 | |
| PFCF ratio | -6.3 | -7.91 | -1.87 | -0.16 | -1.73 | |
| P/B Ratio | 3.72 | 11.82 | 1.93 | 0.08 | 1.12 | |
| PTB ratio | 3.72 | 11.82 | 1.93 | 0.08 | 1.12 | |
| EV to sales | 0 | 0 | 0 | 0 | -495.56 | |
| Enterprise value over EBITDA | -1.67 | -2.53 | -0.78 | 2.74 | 0.22 | |
| EV to operating cash flow | -4.53 | -6.98 | -0.79 | 2.69 | 0.32 | |
| EV to free cash flow | -4.4 | -6.98 | -0.79 | 2.69 | 0.32 | |
| Earnings yield | -0.49 | -0.35 | -0.54 | -3.31 | -0.66 | |
| Free cash flow yield | -0.16 | -0.13 | -0.54 | -6.34 | -0.58 | |
| Debt to equity | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Net debt to EBITDA | 0.72 | 0.34 | 1.07 | 2.9 | 1.4 | |
| Current ratio | 6.78 | 2.89 | 7.69 | 2.85 | 3.78 | |
| Interest coverage | 917.09 | -761.95 | 0 | -8.96 | 0 | |
| Income quality | 0.33 | 0.36 | 0.99 | 0.84 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 961.14 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 1.31K | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -7.14 | |
| Capex to depreciation | -12.59 | -0.09 | -0.06 | 0 | -7.14 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 31.71 | |
| Graham number | 3.62K | 1.02K | 733.23 | 170.05 | 13.49 | |
| ROIC | -1.7 | -4.01 | -1.03 | -0.4 | -0.93 | |
| Return on tangible assets | -1.55 | -2.7 | -0.91 | -0.18 | -0.55 | |
| Graham Net | 538.98 | 93.59 | 147.1 | 67.08 | 3.22 | |
| Working capital | 12.04M | 6.99M | 14.43M | 21.75M | 16.55M | |
| Tangible asset value | 12.29M | 7.2M | 14.6M | 21.75M | 16.69M | |
| Net current asset value | 11.94M | 6.92M | 14.38M | 21.75M | 16.42M | |
| Invested capital | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.34M | 1.61M | 1.7M | 769K | 764.5K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 13.7K | 14.03K | 4.21K | 9.23K | 42.81K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.03 | 0.03 | 0.09 | 0.04 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.82 | -4.11 | -1.04 | -0.28 | -0.75 | |
| Capex per share | -9.83 | -0.06 | -0.03 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0.31 | -0.53 | -0.15 | -0.75 | -1.05 | |
| Operating cash flow per share | -0.57 | -0.5 | -0.4 | -0.55 | -0.67 | |
| Free cash flow per share | -0.57 | -0.5 | -0.4 | -0.56 | -0.67 | |
| Cash per share | 10.49 | 6.09 | 5.67 | 5.09 | 4.42 | |
| Book value per share | 6.84 | 4.05 | 4.98 | 4.25 | 3.28 | |
| Tangible book value per share | 6.84 | 4.05 | 4.98 | 4.25 | 3.28 | |
| Share holders equity per share | 6.84 | 4.05 | 4.98 | 4.25 | 3.28 | |
| Interest debt per share | -1.78 | 0.02 | 0 | 0.04 | 0.04 | |
| Market cap | 18.25M | 28.75M | 17.69M | 19.33M | 18.8M | |
| Enterprise value | -15.11M | -2.07M | -11M | -6.29M | -3.44M | |
| P/E ratio | 4.59 | -2.67 | -6.03 | -1.27 | -0.88 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 4.7K | |
| POCF ratio | -10.1 | -11.29 | -8.65 | -6.87 | -5.54 | |
| PFCF ratio | -10.1 | -11.27 | -8.65 | -6.78 | -5.52 | |
| P/B Ratio | 0.84 | 1.4 | 0.7 | 0.9 | 1.13 | |
| PTB ratio | 0.84 | 1.4 | 0.7 | 0.9 | 1.13 | |
| EV to sales | 0 | 0 | 0 | 0 | -859.2 | |
| Enterprise value over EBITDA | 5.86 | 0.85 | 1.6 | 1.62 | 0.61 | |
| EV to operating cash flow | 8.36 | 0.81 | 5.38 | 2.24 | 1.01 | |
| EV to free cash flow | 8.36 | 0.81 | 5.38 | 2.21 | 1.01 | |
| Earnings yield | 0.05 | -0.09 | -0.04 | -0.2 | -0.28 | |
| Free cash flow yield | -0.1 | -0.09 | -0.12 | -0.15 | -0.18 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0 | 0 | 0.01 | 0.01 | |
| Net debt to EBITDA | 12.95 | 12.65 | 4.17 | 6.58 | 3.93 | |
| Current ratio | 2.85 | 2.87 | 7.32 | 5.54 | 3.78 | |
| Interest coverage | 1.84 | -30 | 0 | 0 | 0 | |
| Income quality | 0.39 | 0.98 | 2.79 | 0.74 | 0.64 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 450.5 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 965.25 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -2.25 | |
| Capex to depreciation | 0 | -4 | 0 | -37 | -2.25 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 25 | |
| Graham number | 6.94 | 6.96 | 4.03 | 8.48 | 8.79 | |
| ROIC | 0.1 | -0.13 | -0.15 | -0.18 | -0.33 | |
| Return on tangible assets | 0.03 | -0.09 | -0.03 | -0.14 | -0.23 | |
| Graham Net | 6.79 | 3.92 | 4.88 | 4.13 | 3.22 | |
| Working capital | 21.75M | 20.5M | 25.19M | 21.42M | 16.55M | |
| Tangible asset value | 21.75M | 20.51M | 25.2M | 21.55M | 16.69M | |
| Net current asset value | 21.75M | 20.5M | 25.19M | 21.27M | 16.42M | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 891.5K | 913.5K | 1.04M | 1.47M | 1.4M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 63.72K | 100.71K | 0 | 178.29K | 18.47K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.05 | -0.13 | -0.03 | -0.18 | -0.32 | |
| Capex per share | 0 | 0 | 0 | -0.01 | 0 |
NRBO Frequently Asked Questions
What is NeuroBo Pharmaceuticals, Inc. stock symbol ?
NeuroBo Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol NRBO
What is NeuroBo Pharmaceuticals, Inc. stock quote today ?
NeuroBo Pharmaceuticals, Inc. stock price is $3.46 today.
Is NeuroBo Pharmaceuticals, Inc. stock public?
Yes, NeuroBo Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.37M
- Market Capitalization 17.71M
- Employee 8
- CEO Mr. Hyung-Heon Kim
- Headquarters Boston,MA,US
- IPO Date 2016-08-05
-
Website
https://www.neurobopharma.com 
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
